Abstracts tagged "SF36"

Abstract Number: 0890 • ACR Convergence 2021
Depression Is Associated with Frailty in Systemic Lupus Erythematosus Patients: Multicenter Retrospective Analysis Using Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index
Kichul Shin¹, In Ah Choi², Eunyoung Lee³, SE RIM CHOI⁴, Jina Yeo⁵, Yun Jong Lee⁶, Su-Jin Yoo⁷, Bong-Jin Hahm⁴, Jee Eun Park⁴, Ju Ho Lee⁸, Yeong-Wook Song⁴ and Ju Yeon Kim⁴, ¹Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Uijeongbu Eulji Medical Center, Seoul, South Korea, ⁴Seoul National University Hospital, Seoul, Republic of Korea, ⁵Gil Medical Center, Seoul, South Korea, ⁶Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea, ⁷Chungnam National University Hospital, Daejeon, Republic of Korea, ⁸Seoul National University Bundang Hospital, Yongin Si, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus International Collaborating Clinics-Frailty Index (SLICC-FI) is a novel health measure in systemic lupus erythematosus (SLE) and was reported to have impact…
Abstract Number: 1822 • ACR Convergence 2021
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Peter C Taylor¹, Andrew G Bushmakin², Joseph C Cappelleri², Pamela Young³, Rebecca Germino², Joseph Merola⁴ and Gil Yosipovitch⁵, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵University of Miami Miller School, Florida, FL
Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
Abstract Number: 0025 • ACR Convergence 2020
Clinical and Psychological Assessment of Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study
Tian Liu¹, Chao Gao¹ and Lihong Chen¹, ¹hospital, Beijing, China (People's Republic)
Background/Purpose: To assess the clinical features and psychological status of the rheumatoid arthritis(RA) patients with fibromyalgia(FM) in a real-world observational setting.Methods: Between December 2018 to…
Abstract Number: 0136 • ACR Convergence 2020
Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
Clifton Bingham III¹, David Walker², Peter Nash³, Susan Lee⁴, Lei Ye⁴, Hao Hu⁴, Javaria Mona Khalid⁵ and Bernard Combe⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶University of Montpellier, Montpellier, France
Background/Purpose: Reduction in pain and fatigue, maintenance of physical functioning, and improvement in health-related quality of life (HRQoL) are vital aspects of successful treatment for…
Abstract Number: 0353 • ACR Convergence 2020
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Laura Coates¹, Philip Mease², Dafna Gladman³, Sandra Navarra⁴, Weibin Bao⁵ and Corine Gaillez⁶, ¹University of Oxford, Oxford, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Santo Tomas, Manila, Philippines, ⁵Novartis Pharmaceuticals Corporation, East Hannover, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: A treat-to-target approach in psoriatic arthritis (PsA) was recommended by EULAR and GRAPPA to achieve remission (REM) or low disease activity (LDA), by regular…
Abstract Number: 1102 • ACR Convergence 2020
Neuropathic Pain in Inflammatory Hand Osteoarthritis(OA) Lowers Quality of Life and May Require Another Approach Than Anti-inflammatory Treatment
Coen van der Meulen¹, Lotte van de Stadt¹, Féline Kroon², Marion Kortekaas¹, Annelies Boonen³, Stefan Böhringer⁴, Monique Reijnierse², Frits Rosendaal², Naghmeh Riyazi⁵, Mirian Starmans⁶, Franktien Turkstra⁷, Jende Van Zeben⁸, CF Allaart² and Margreet Kloppenburg², ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴LUMC, Leiden, ⁵HAGA ziekenhuis, the hague, Netherlands, ⁶Zuyderland MC, Heerlen, Netherlands, ⁷Reade, Amsterdam, Netherlands, ⁸Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
Background/Purpose: To investigate whether neuropathic pain is present in patients with inflammatory hand OA, to investigate characteristics of those patients and the impact of neuropathic…
Abstract Number: 1363 • ACR Convergence 2020
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
Vibeke Strand¹, Gurjit Kaeley², Martin Bergman³, Dafna Gladman⁴, Laura Coates⁵, Peter Hur⁶, Nina Kim⁷, Bhumik Parikh⁶, Patricia Pertel⁸ and Philip Mease⁹, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Florida College of Medicine - Jacksonville, Jacksonville, FL, ³Drexel University College of Medicine, Philadelphia, PA, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Oxford, Oxford, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁸Novartis AG, Basel, Switzerland, ⁹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: The phase 3 randomized controlled trial FUTURE 5 (NCT02404350) showed the efficacy of secukinumab (SEC) improving clinical signs, symptoms, and radiographic progression in patients…
Abstract Number: 1868 • ACR Convergence 2020
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Sofia Exarchou⁴, Roberta Ramonda⁵, Marleen van de Sande⁶, Désirée van der Heijde⁷ and Floris van Gaalen⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ⁵University of Padova, Padova, Italy, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: The aim of this study was to compare quality of life (QoL) between chronic back pain (CBP) patients with and without a diagnosis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].